Lunai Bioworks Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Lunai Bioworks Inc. (LNAI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.00% for the 12-month period ending 2022-06-30, per its 10-K filed 2023-02-27.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2023-02-27
- Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-09-30 was 0.87%, a 0.00% change year-over-year.
- Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-09-30 was 0.87%.
- Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 0.00%, a 100.00% decline from fiscal 2021.
- Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.08%.
- Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 0.87%.
- Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2014 was 0.41%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2022-06-30 | 0.00% 10-K · filed 2023-02-27 | ||||
| 2021-06-30 | 0.08% 10-K · filed 2021-09-24 | ||||
| 2018-03-31 | 0.87% 10-Q · filed 2018-05-15 | ||||
| 2017-12-31 | 0.87% 10-Q · filed 2018-02-09 | ||||
| 2017-09-30 | 0.87% 10-Q · filed 2017-11-20 | ||||
| 2017-06-30 | 0.87% 10-K · filed 2017-11-20 | ||||
| 2017-03-31 | 0.87% 10-Q · filed 2017-05-15 | ||||
| 2016-12-31 | 0.87% 10-Q · filed 2017-02-14 | ||||
| 2016-09-30 | 0.87% 10-Q · filed 2016-11-14 | ||||
| 2014-12-31 | 0.41% 10-K · filed 2015-03-31 | ||||
| 2014-09-30 | 0.41% 10-Q · filed 2014-11-13 | ||||
| 2014-06-30 | 0.41% 10-Q · filed 2014-08-14 | ||||
| 2013-12-16 | 0.41% 10-KT · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |